Search
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalAs a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects. … [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Products: TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADETDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073].
Products: Dalbavancin Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Dalbavancin ratiopharm 500 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: ZELBORAF 240 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLET, ZELBORAF ® TABLETAS LACADAS DE 240 MGPrednisolone hemisuccinate
go.drugbank.com/drugs/DB14633InvestigationalCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: Prednisolut 100 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung, Prednisolut 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/InfusionslösungCycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Products: SIKLOCAP 250 MG KAPSUL, 500 ADET, SIKLOCAP 250 MG KAPSUL, 40 ADETFomepizole
go.drugbank.com/drugs/DB01213ApprovedVet approvedFomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsProducts: Fomepizol SERB 5 mg/ml Konzentrat zur Herstellung einer InfusionslösungAdrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency
smpdb.ca/view/SMP0000372DiseaseTestosterone must be replaced for genetically males (XY) to induce puberty and continued throughout adult life. … Genetically female patients need female hormone replacement to induce puberty and regulate menses. Surgery may be needed for males with ambiguous genitalia.
Fosfomycin
go.drugbank.com/drugs/DB00828ApprovedInvestigational[A230348] Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated … Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.
Products: SOLUFOS® 500 MG, Fomicyt 40 mg/ml Pulver zur Herstellung einer InfusionslösungPropiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate) … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: MİCTONORM 5 MG KAPLI TABLET, 98 ADET, MİCTONORM 15 MG KAPLI TABLET, 56 ADETGadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigational[A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained … that provides contrast enhancement of the brain, spine, and surrounding tissues, resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to
Synonyms: gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate, GD-HP-DO 3AProducts: ProHance 279.3 mg/ml solution for injection